Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF EMICIZUMAB GIVEN EVERY 2 WEEKS AND 4 WEEKS IN HEMOPHILIA A PEDIATRIC PATIENTS AGED LESS THAN 12 YEARS WITHOUT FVIII INHIBITORS

Trial Profile

A MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF EMICIZUMAB GIVEN EVERY 2 WEEKS AND 4 WEEKS IN HEMOPHILIA A PEDIATRIC PATIENTS AGED LESS THAN 12 YEARS WITHOUT FVIII INHIBITORS

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Emicizumab (Primary)
  • Indications Haemophilia A
  • Focus Registrational; Therapeutic Use
  • Acronyms HOHOEMI
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 04 Dec 2018 Results assessing efficacy and safety of emicizumab in Q2W and Q4W in patients with hemophilia patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
    • 04 Dec 2018 According to a Chugai Pharmaceutical media release, data were presented at the 60th American Society of Hematology (ASH) Annual Meeting.
    • 16 Feb 2018 Planned number of patients changed from 12 to 13.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top